Introduction
The use of heparin by continuous infusion in patients with recent myocardial infarction or impaired myocardial function may be attended by special difficulties, since it is desirable in such patients to avoid the infusion of saline. Five per cent dextrose has been criticized as a vehicle for the administration of heparin on the grounds that the anticoagulant may lose potency if it is in solution for any length of time at the relatively low pH of dextrose (Pritchard, 1964; O'Riordan and MacGowan, 1970) . Presumably as a result of these statements, recent authoritative publications giving information on incompatibilities of drugs with infusion fluids have again stressed that heparin should not be diluted in dextrose (Drug and Therapeutics Bulletin, 1970; Girdwood, 1971 Blood was taken four times during a 12-hour infusion period (at 3, 6, 9, and 12 hours) for estimation of P.T.T.K. and plasma heparin level. These investigations were performed on citrated plasma by the methods described by Dacie and Lewis (1968) . The normal range for P.T.T.K. is 30-45 seconds.
In a further 20 patients continuous drip infusion of heparin was given into a peripheral vein about 2 in (5 cm) above the wrist with either dextrose or sorbitol for a period of eight days to compare the incidence of local phlebitis from the two diluents.
Results
Heparin Requirements.-The daily dose of heparin initially required to maintain the P.T.T.K. between 80 and 120 seconds ranged from 28,000 to 40,000 units (from 330 to 550 U/kg/24 hr).
No haemorrhagic complications were observed during the study.
Variations Incidence of Thrombophlebitis.-Ten patients had constant drip infusion of heparin in dextrose for eight days; one developed phlebitis on the sixth day. Of the 10 patients who received heparin in sorbitol two developed phlebitis on the fourth infusion day. This relatively small incidence of phlebitis might have been due in part to the low infusion rates.
Discussion
The results of this investigation suggest that both 5%' dextrose and 5% sorbitol are suitable diluents for heparin by constant drip infusion. Pritchard (1964) reported that heparin became unstable when autoclaved at pH below 5 and suggested that the anticoagulant might lose its potency when mixed with dextrose. Since then it has been suggested, without actual experimental proof, that dextrose is an unsuitable diluent for heparin. However, our results indicate that the effectiveness of a heparindextrose solution does not alter during a 12-hour infusion period. If loss of potency of heparin had occurred, one might expect to find less effective heparinization-that is, a shortened P.T.T.K. and lower plasma heparin level in samples of blood taken at 12 hours than at three hours; we found no difference between such samples. We cannot, of course, rule out the possibility that some decrease in potency may occur with solutions of dextrose at a lower pH than the range we were using (3-8 to 4 5), but the lower limit of the B.P. specification is set at 3-5.
Despite careful control of the infusion some variation in plasma heparin level and a wider variation in P.T.T.K. were observed during the 12-hour period. Some variations may occur even when heparin is administered by constant infusion pump, although Handley (1967) showed that the use of such a pump maintains a more consistent prolongation of the whole blood clotting time.
The initial level of P.T.T.K. in the present study (80-120 seconds) was longer than that advocated by some writers (Spector and Corn, 1967; Hirsh et al., 1970) . During the test infusions even longer times were observed but no episode of bleeding occurred in any patient. Plasma heparin levels remained, with two exceptions, within an acceptable range of 0-5-1-5 U/ml. The two tests do not, of course, measure the same aspects of heparin activity in the blood; the difficulties of correlating various methods of control of heparin therapy have been discussed by Pitney et al. (1970) . The results of the present study suggest that satisfactory plasma heparin levels may be accompanied by a P.T.T.K. outside the generally recommended range.
No constant pattern of heparin requirements emerged; heparin dosage was not closely related to body weight. Despite the trend towards prolongation of the P.T.T.K. at eight days compared with five days, there was no acceptable evidence that the patients had become increasingly sensitive to heparin. These findings are in keeping with those of Pombo et al. (1970) , who were unable to find any consistent change in heparin requirements during the two weeks following myocardial infarction.
Adjustments of dose are necessary to maintain consistent prolongation of the P.T.T.K. during treatment; the pattern of such adjustments is not predictable without laboratory control. Judging by the findings in the present study, the widespread practice of giving a constant dose of heparin (often 40,000 units daily) by intravenous infusion may result in overdosage, and theoretically runs the risk of haemorrhage. With adequate laboratory control heparin can be used satisfactorily as a continuous infusion, and both dextrose and sorbitol are suitable as diluents when it is necessary to avoid the use of saline.
